Online first
Short communication
Published online: 2024-02-06

open access

Page views 176
Article views/downloads 42
Get Citation

Connect on Social Media

Connect on Social Media

The efficacy and safety of sodium-glucose cotransporter inhibitors in cancer patients with heart failure-a single-centre experience

Katarzyna Styczkiewicz12, Andrzej Sokołowski3
Pubmed: 38348615

Abstract

Not available

Article available in PDF format

View PDF Download PDF file

References

  1. Lelonek M, Grabowski M, Kasprzak JD, et al. An expert opinion of the Heart Failure Association of the Polish Cardiac Society on the 2021 European Society of Cardiology guidelines for the diagnosis and treatment of acute and chronic heart failure: Heart failure guidelines from a national perspective. Kardiol Pol. 2022; 80(2): 239–246.
  2. Spiazzi BF, Naibo RA, Wayerbacher LF, et al. Sodium-glucose cotransporter-2 inhibitors and cancer outcomes: A systematic review and meta-analysis of randomized controlled trials. Diabetes Res Clin Pract. 2023; 198: 110621.
  3. Gongora CA, Drobni ZD, Quinaglia Araujo Costa Silva T, et al. Sodium-glucose co-transporter-2 inhibitors and cardiac outcomes among patients treated with anthracyclines. JACC Heart Fail. 2022; 10(8): 559–567.
  4. Chiang CH, Chiang CH, Chiang CH, et al. Impact of sodium-glucose cotransporter-2 inhibitors on heart failure and mortality in patients with cancer. Heart. 2023; 109(6): 470–477.
  5. Benedetti R, Benincasa G, Glass K, et al. Effects of novel SGLT2 inhibitors on cancer incidence in hyperglycemic patients: a meta-analysis of randomized clinical trials. Pharmacol Res. 2022; 175: 106039.
  6. Quagliariello V, De Laurentiis M, Rea D, et al. The SGLT-2 inhibitor empagliflozin improves myocardial strain, reduces cardiac fibrosis and pro-inflammatory cytokines in non-diabetic mice treated with doxorubicin. Cardiovasc Diabetol. 2021; 20(1): 150.
  7. Min J, Wu L, Liu Y, et al. Empagliflozin attenuates trastuzumab-induced cardiotoxicity through suppression of DNA damage and ferroptosis. Life Sci. 2023; 312: 121207.
  8. Al-Kindi SG, Oliveira GH. Prevalence of preexisting cardiovascular disease in patients with different types of cancer: the unmet need for onco-cardiology. Mayo Clin Proc. 2016; 91(1): 81–83.



Polish Heart Journal (Kardiologia Polska)